Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IMA203 Product, IMA203 product- flat dose, anzutresgene autoleucel, anzu-cel
IMA203 · 3 trials · 8 indications
progression-free survival (PFS), centrally assessed (by blinded independent central review) using RECIST 1.1
Number of patients with dose-limiting toxicities (DLTs)
Treatment emergent adverse events (TEAEs), Adverse events of special interest (AESIs) and Treatment-emergent serious adverse events (TESAEs).
Objective response rate (ORR) based on best overall response (BOR) of complete response (CR) and partial response (PR) centrally assessed (by a BICR1) using RECIST1.1
Number of DLTs will be used to determine the maximum tolerated dose (MTD) and/or recommended dose for extension (RDE) after treatment with IMA203 product in combination with mRNA-4203
Used to evaluate safety and tolerability of treatment with IMA203 in combination with mRNA-4203
| Arm | Type | Description |
|---|---|---|
| Experimental arm | EXPERIMENTAL | Non-myeloablative chemotherapy for lymphodepletion (LD) over 4 days using fludarabine (FLU) and cyclophosphamide (CY), one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy |
| Control arm- investigator's choice | ACTIVE_COMPARATOR | Investigator's choice of treatment approved by the respective Competent Authority (nivolumab plus relatlimab \[Opdualag®\], lifileucel, nivolumab, pembrolizumab, ipilimumab, or chemotherapy \[e.g., dacarbazine, temozolomide, paclitaxel, alb-bound paclitaxel, or paclitaxel plus carboplatin\]) as determined by the site investigator in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC), optional bridging therapy. |
| Dose Escalation A (closed to enrollment) | EXPERIMENTAL | Dose escalation of IMA203 |
| Extension Cohort A | EXPERIMENTAL | IMA203 at RP2D |
| Extension Cohort B (closed to enrollment) | EXPERIMENTAL | IMA203 at RP2D + nivolumab |
| Extension Cohort AA | EXPERIMENTAL | IMA203 at final RP2D (flat dose) |
| Uveal Melanoma | EXPERIMENTAL | IMA203 at RP2D |
| Dose Escalation B | EXPERIMENTAL | Dose escalation of IMA203CD8 |
| Extension Cohort C | EXPERIMENTAL | IMA203CD8 at dose levels confirmed to be safe |
| Extension Cohort D | EXPERIMENTAL | IMA203CD8 at dose levels confirmed to be safe; without IL-2 |
| Ovarian | EXPERIMENTAL | IMA203CD8 monotherapy at dose levels confirmed to be safe |
| Endometrial | EXPERIMENTAL | IMA203CD8 monotherapy at dose levels confirmed to be safe |
| Head and Neck, Lung, and Triple Negative Breast Cancer | EXPERIMENTAL | IMA203CD8 monotherapy at dose levels confirmed to be safe |
| Rare Cancers | EXPERIMENTAL | IMA203CD8 monotherapy at dose levels confirmed to be safe |
| IMA203 with mRNA-4203 in participants with metastatic cutaneous melanoma or synovial sarcoma | EXPERIMENTAL | This is a non-comparative, open-label trial with different cohorts investigating IMA203 in combination with mRNA-4203. |
| Name | Type | Description |
|---|---|---|
| IMA203 | BIOLOGICAL | one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy |
| nivolumab plus relatlimab | BIOLOGICAL | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| lifileucel | BIOLOGICAL | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| nivolumab | BIOLOGICAL | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| pembrolizumab | BIOLOGICAL | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| ipilimumab | BIOLOGICAL | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| Dacarbazine | DRUG | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| temozolomide | DRUG | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| paclitaxel | DRUG | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| paclitaxel plus carboplatin | DRUG | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| Albumin-Bound Paclitaxel | DRUG | in accordance with current respective prescribing information (PI) and/or summary of product characteristics (SmPC) |
| IMA203 Product | BIOLOGICAL | The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula |
| IMA203 product- flat dose | BIOLOGICAL | The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells |
| IMA203CD8 Product | BIOLOGICAL | The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula |
| IMADetect® | DEVICE | IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials. |
| mRNA-4203 | BIOLOGICAL | mRNA-4203 will be administered starting on Day 15 after IMA203 infusion at the earliest. mRNA-4203 will be given for 12 cycles (28 day cycle length); during Cycle 1 it will be given on Day 1 and Day 15 and in Cycles 2-12 it will be given on Day 1. |
Inclusion Criteria: * Pathologically confirmed and documented cutaneous melanoma or mucosal melanoma. CM patients (including acral melanoma and melanoma of unknown primary) and mucosal melanoma patients with unresectable or metastatic disease * Positive for HLA-A\*02:01 or one of its P-group allele...
IMA203 is an investigational cell therapy developed by Immatics N.V. for advanced cancers, including cutaneous melanoma and other refractory solid tumors. It is designed to target PRAME, a protein expressed in multiple tumor types, and is being studied both as monotherapy and in combination with other agents in clinical trials.
IMA203 targets PRAME, a cancer-associated protein presented on tumor cells. The therapy is designed to direct a T cell response against PRAME-expressing tumors. PRAME is the molecular target underlying the program, which Immatics is developing across melanoma and other refractory solid tumor settings.
IMA203 is being developed by Immatics N.V., a biopharmaceutical company listed under the ticker IMTX. Immatics is running the clinical program, including a Phase 3 study in previously treated cutaneous melanoma and earlier-stage studies in solid tumors and in combination with mRNA-4203.
IMA203 is in Phase 3 development. The SUPRAME study, NCT06743126, is a randomized Phase 3 trial comparing IMA203 against investigator's choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma. IMA203 also continues in Phase 1 studies. It has received RMAT designation from the FDA.
IMA203 is being studied in three recruiting trials. NCT06743126 is the Phase 3 SUPRAME study in cutaneous and mucosal melanoma across the United States, Canada, and Europe. NCT03686124 is a Phase 1 study in refractory solid tumors, and NCT06946225 is a Phase 1 study combining IMA203 with mRNA-4203 in cutaneous melanoma and synovial sarcoma.
Yes. IMA203, IMA203 product, and IMA203 product flat dose refer to the same Immatics cell therapy program targeting PRAME. These names appear across the company's clinical trial listings and program descriptions for the melanoma and refractory solid tumor studies.